Table 7.
Effects of resveratrol formulations on cell viability (a) and ROS levels (b) in AMD patient # 5.
| (a) AMD PATIENT #5_Resveratrol Effects on Cell Viability. | |||
| Cell Viability | Percent Increase/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 42% 0.0021 |
1 ± 0.008937 | 1.420 ± 0.01545 |
| AMD UN vs. AMD B2-treated | 35.2% 0.0021 |
1 ± 0.008937 | 1.352 ± 0.02627 |
| AMD UN vs. AMD B3-treated | 23.9% 0.0021 |
1 ± 0.008937 | 1.239 ± 0.005641 |
| AMD UN vs. AMD B4-treated | 67% 0.0021 |
1 ± 0.008937 | 1.670 ± 0.01759 |
| AMD UN vs. AMD B5-treated | 23% 0.0021 |
1 ± 0.008937 | 1.230 ± 0.01031 |
| AMD UN vs. AMD B6-treated | 50.2% 0.0021 |
1 ± 0.008937 | 1.502 ± 0.05886 |
| (b) AMD PATIENT #5_Resveratrol Effects on ROS Levels. | |||
| Ros Levels | Percent Decrease/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 40.36% 0.0012 |
1 ± 0.02983 | 0.5964 ± 0.02554 |
| AMD UN vs. AMD B2-treated | 43.83% 0.0012 |
1 ± 0.02983 | 0.5617 ± 0.01594 |
| AMD UN vs. AMD B3-treated | 32.1% 0.0022 |
1 ± 0.02983 | 0.6790 ± 0.04663 |
| AMD UN vs. AMD B4-treated | 1.6% 1.0000 ns |
1 ± 0.02983 | 1.016 ± 0.01649 |
| AMD UN vs. AMD B5-treated | 20.35% 0.0238 |
1 ± 0.02983 | 0.7965 ± 0.008948 |
| AMD UN vs. AMD B6-treated | 16.39% 0.0238 |
1 ± 0.02983 | 0.8361 ± 0.003819 |